Ве молиме користете го овој идентификатор да го цитирате или поврзете овој запис: http://hdl.handle.net/20.500.12188/30186
DC FieldValueLanguage
dc.contributor.authorIskra Velevskaen_US
dc.contributor.authorJovana Aleksoven_US
dc.contributor.authorEvgenija Mihajloskaen_US
dc.contributor.authorAleksandar Dimkovskien_US
dc.contributor.authorIrina Panovska-Stavridisen_US
dc.contributor.authorMilena Stevanovicen_US
dc.contributor.authorAleksandra Grozdanovaen_US
dc.date.accessioned2024-05-15T08:02:25Z-
dc.date.available2024-05-15T08:02:25Z-
dc.date.issued2022-
dc.identifier.urihttp://hdl.handle.net/20.500.12188/30186-
dc.language.isoenen_US
dc.relation.ispartofMacedonian pharmaceutical bulletinen_US
dc.titleUse of tocilizumab for treatment of COVID-19 from off-label to extended indicationen_US
dc.typeOtheren_US
dc.identifier.doi10.33320/maced.pharm.bull.2022.68.03.277-
item.fulltextNo Fulltext-
item.grantfulltextnone-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Pharmacy-
crisitem.author.deptFaculty of Medicine-
Appears in Collections:Faculty of Medicine: Other
Прикажи едноставен запис

Page view(s)

66
checked on 4.5.2025

Google ScholarTM

Проверете

Altmetric


Записите во DSpace се заштитени со авторски права, со сите права задржани, освен ако не е поинаку наведено.